Ophthalmic Plastic and Reconstructive Surgery · Great Neck, NY
NPI
1336174374
Since 2006
Specialty
Ophthalmic Plastic and Reconstructive Surgery
Code 207WX0200X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
287 Northern Blvd Ste 101
Great Neck, NY, 11021
Phone (516) 829-2020
Groups this clinician bills Medicare through
Medicare paid, 2024
$351K
6,865 services
Medicare patients, 2024
168
Average age 75
Drug cost, 2024
$998K
4,214 prescriptions
Company payments, 2025
$1,178
From 8 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Daniel K Khodadadian was code 95004 (test - miscellaneous), 3,301 times for 53 patients. In total Daniel K Khodadadian billed 6,865 services in 42 codes, and Medicare paid $351K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2017-01-23.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 95004 Test - Miscellaneous | Office | 3,301 | 53 | $3.50 | $12K |
| 92285 Standard X-ray | Office | 406 | 167 | $19.22 | $7,805 |
| 83861 Clinical Chemistry | Office | 370 | 128 | $22.03 | $8,151 |
| 92014 Ophthalmological E&M | Office | 348 | 142 | $101.60 | $35K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 269 | 118 | $14.28 | $3,841 |
| 68761 Eye | Office | 215 | 110 | $146.12 | $31K |
| 95060 Test - Miscellaneous | Office | 179 | 95 | $36.09 | $6,460 |
| 76512 Ultrasound - Nonspecific | Office | 176 | 118 | $79.61 | $14K |
| 92250 Angiography | Office | 162 | 117 | $31.83 | $5,156 |
| 65778 Eye | Office | 136 | 80 | $1,010.96 | $137K |
| 92273 Test - Miscellaneous | Office | 120 | 108 | $114.94 | $14K |
| 92283 Ophthalmological E&M | Office | 118 | 105 | $41.74 | $4,925 |
| 92100 Vision, Hearing, and Speech Services | Office | 118 | 95 | $72.55 | $8,561 |
| 92083 Vision, Hearing, and Speech Services | Office | 116 | 93 | $57.24 | $6,639 |
| 92134 Computerized Ophthalmic Imaging | Office | 115 | 83 | $32.77 | $3,768 |
By year: 2022 $113K for 1,562 services; 2023 $358K for 6,655 services; 2024 $351K for 6,865 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 83861 Clinical Chemistry | 370 | 128 | $22.03 | $8,151 |
Medicare prescription drug claims, 2024
In 2024, the drug Daniel K Khodadadian prescribed most often to Medicare patients was Latanoprost, with 763 prescriptions and refills. In total Daniel K Khodadadian wrote 4,214 Medicare prescriptions that cost $998K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Latanoprost Generic | 763 | 1,248 | 204 | $6,527 |
| Restasis Multidose Cyclosporine | 507 | 543 | 165 | $322K |
| Vyzulta Latanoprostene Bunod | 322 | 403 | 81 | $117K |
| Azelastine Hcl Generic | 308 | 317 | 98 | $4,296 |
| Brimonidine Tartrate Generic | 241 | 362 | 68 | $19K |
| Restasis Cyclosporine | 208 | 244 | 63 | $149K |
| Simbrinza Brinzolamide/Brimonidine Tart | 207 | 227 | 40 | $44K |
| Prednisolone Acetate Generic | 160 | 202 | 86 | $8,611 |
| Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat | 154 | 247 | 48 | $2,309 |
| Neomycin-Polymyxin-Dexameth Neomycin/Polymyxin B/Dexametha | 144 | 149 | 93 | $1,482 |
| Cyclosporine Generic | 95 | 107 | 35 | $25K |
| Ofloxacin Generic | 89 | 97 | 53 | $1,693 |
| Ketorolac Tromethamine Generic | 87 | 100 | 56 | $2,084 |
| Xiidra Lifitegrast | 86 | 118 | 29 | $80K |
| Lumigan Bimatoprost | 85 | 132 | 22 | $34K |
Brand drugs: 2,366 claims; generic drugs: 1,848 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Daniel K Khodadadian $1,178 ($1,178 in general payments such as food, travel and fees) from 8 companies. The largest payer was Amgen Inc. with $320.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.